New Delhi: Bharat Biotech’s COVID-19 vaccine, which has been authorised to be used in the country, is proven to be safe and produced an immune response in a small group of adults in the age group 18-55 years, a study in The Lancet medical journal said.
The vaccine, developed in association with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, that kicked off in November. Bharat Biotech on Friday said that 13,000 people taking part in the late-stage trial had been given the second dose, reported news agency Reuters.
Two formulations of the vaccine, called COVAXIN, have been picked for testing in more advanced stages and further efficacy trials are warranted, the agency report said.
COVAXIN is an inactivated vaccine that introduces dead virus into the body to trigger an immune response.
ALSO READ: India To Start Exporting COVID-19 Vaccines To Six Neighbouring Countries Today
Stay ahead with Odisha Bytes Breaking News - your ultimate source for the fastest, most…
New Delhi: After the record-breaking success of ‘Pushpa 2: The Rule’, Rashmika Mandanna has her…
Bhubaneswar: Twelve members of Village Water and Sanitation Committees (VWSC) from nine districts of Odisha…
Hyderabad: Bollywood actress Janhvi Kapoor, who is rumoured to be dating Shikhar Pahariya, had once…
Bhubaneswar: In a remarkable stride toward strengthening industrial ecosystem, the Odisha government on Wednesday approved…
Bengaluru: Playing away from home, Odisha FC turned the game on its head to snatch a…
This website uses cookies.
